These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 496148)
1. [The use of synthetic antiparkinson agents as antidepressive agents]. Wirth JF Ann Med Psychol (Paris); 1979; 137(3-4):245-50. PubMed ID: 496148 [No Abstract] [Full Text] [Related]
2. Combined treatment in Parkinson's disease. Wheatley D Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232 [No Abstract] [Full Text] [Related]
3. [Clinical study of the therapeutic effects of tofenacine in depressive states. Pilot study of 100 cases]. Brasseur R Encephale; 1971; 60(3):265-79. PubMed ID: 5119349 [No Abstract] [Full Text] [Related]
4. [Pilot study on the effects of an antiparkinson anticholinergic agent during depressive conditions]. Gisselmann A; Marin A; Simon P Encephale; 1975; 1(4):363-6. PubMed ID: 1220958 [TBL] [Abstract][Full Text] [Related]
5. Thiothixene in the treatment of anxiety and depression in outpatients. Simeon J; Nikolovski OT; Spero M Curr Ther Res Clin Exp; 1970 Jun; 12(6):369-76. PubMed ID: 4988235 [No Abstract] [Full Text] [Related]
6. [Antagonism between anti-Parkinson drugs and neuroleptics. Apropos of various withdrawal experiences, a personal one among them (2nd part)]. Bourgeois M; Bouey P Ann Med Psychol (Paris); 1976 Nov; 2(4):669-708. PubMed ID: 1020864 [No Abstract] [Full Text] [Related]
7. Excessive use of anticholinergic drugs in a sub-sample of Italian schizophrenics. Schifano F; di Costanzo E Int J Clin Pharmacol Ther Toxicol; 1991 May; 29(5):184-6. PubMed ID: 2071270 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effectiveness of modern antiparkinson agents]. Kurako IuL; Volianskiĭ VE; Fadeev SM Vrach Delo; 1981 Feb; (2):7-11. PubMed ID: 7222616 [No Abstract] [Full Text] [Related]
9. [Fatalities caused by anticholinergic antiparkinsonian drugs. Analysis of findings in a 11-year national material]. Gjerden P; Engelstad KS; Pettersen G; Slørdal L Tidsskr Nor Laegeforen; 1998 Jan; 118(1):42-4. PubMed ID: 9481909 [TBL] [Abstract][Full Text] [Related]
10. Improving psychiatric drug therapy. A matter of dosage and choice. Cole JO; Stotsky BA Geriatrics; 1974 Jun; 29(6):74-8. PubMed ID: 4364716 [No Abstract] [Full Text] [Related]
11. Problems in pharmacological evaluation of potential antiparkinson agents. Metysová J; Metys J; Dlabac A Act Nerv Super (Praha); 1978 Feb; 20(1):55-6. PubMed ID: 565123 [No Abstract] [Full Text] [Related]
13. [Clinical trial of delayed-action Akinophyl (Akineton)]. Delteil P; Decreton C Ann Med Psychol (Paris); 1972 May; 1(5):696-709. PubMed ID: 5081113 [No Abstract] [Full Text] [Related]
14. Patterns of psychotropic drug use for schizophrenia. Laska E; Varga E; Wanderling J; Simpson G; Logemann GW; Shah BK Dis Nerv Syst; 1973; 34(6):294-305. PubMed ID: 4782286 [No Abstract] [Full Text] [Related]
15. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. Myhrer T; Enger S; Aas P Pharmacol Biochem Behav; 2008 Jun; 89(4):633-8. PubMed ID: 18384867 [TBL] [Abstract][Full Text] [Related]
16. Investigations on the effect of some drugs on the Parkinsonian rigidity. Boman K; Meurman T Acta Neurol Scand; 1970; 46(1):71-84. PubMed ID: 5412628 [No Abstract] [Full Text] [Related]
17. [Treatment of parkinsonism]. Parkenberg H Ugeskr Laeger; 1976 Apr; 138(18):1104-5. PubMed ID: 1265907 [No Abstract] [Full Text] [Related]
18. [Long-acting antiparkinson agents. I. Pilot study on benzetimide (342 cases)]. Korn M; Pinchard A; Breulet M; Goffioul F; Bobon J Acta Psychiatr Belg; 1971 Mar; 71(2):65-75. PubMed ID: 5560276 [No Abstract] [Full Text] [Related]
19. [A new synthetic antiparkinsonian drug, tropatepine hydrochloride in extrapyramidal syndromes induced by neuroleptics]. Lambert A; dachary JM; Marie C; Oules J; Pagot R; Sales M; Vauterin C Encephale; 1976; 2(2):115-21. PubMed ID: 776591 [TBL] [Abstract][Full Text] [Related]
20. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents. Costall B; Naylor RJ; Wright T Arzneimittelforschung; 1972 Jul; 22(7):1178-83. PubMed ID: 4404343 [No Abstract] [Full Text] [Related] [Next] [New Search]